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The type I interferon system plays a critical role in host defense
in health, and a growing body of literature suggests that type I
interferon is a critical mediator of human autoimmune disease
(1). Type I interferons function as a bridge between the innate
and adaptive immune systems, and as such play an important
role in setting thresholds for response against self antigens. Many
investigators have focused on the role type I interferons play in
autoimmune disease. This fascinating and rapidly growing body
of literature encompasses many different autoimmune diseases,
including systemic lupus erythematosus, type I diabetes, multi-
ple sclerosis, and others. Type I interferons play differing roles in
human autoimmune conditions. For example, in the autoimmune
diseases, systemic lupus erythematosus and Sjogren’s syndrome,
increased interferon alpha signaling plays a pathogenic role (2,
3). Interestingly, interferon beta is used as a therapeutic in mul-
tiple sclerosis, an autoimmune disease of the central nervous
system (4). Both interferon alpha and beta signal through the
same type I interferon receptor and share many similarities in
downstream signaling, suggesting that the disparate activities of
type I interferons in lupus and multiple sclerosis relate to differ-
ences in the underlying disease processes and immunoregulation
in these two diseases. In this Research Topic, a series of articles
provides a comprehensive overview of the various roles type I
interferons play in autoimmune diseases, with a focus on human
immunology.
This Research Topic features a number of Original Research
Articles, including a study by Mavragani et al. examining type
I interferon levels in the organ-specific autoimmune disorders
type I diabetes and autoimmune thyroid disease (5). They demon-
strate high type I interferon levels in both of these autoimmune
conditions, supporting the idea that high levels of type I inter-
feron are detectable in organ-specific autoimmune conditions in
addition to systemic autoimmune disorders. Clark et al. inves-
tigate genetic polymorphisms in the interferon regulatory factor
5 (IRF5) gene (6). This gene has been associated with suscep-
tibility to systemic lupus erythematosus (7), and they demon-
strate four distinct promoter regions have differential activity.
Ko et al. study type I interferon-induced gene expression in
patients with systemic lupus erythematosus (8). They demon-
strate that the expression of type I interferon-induced genes in
lupus immune cells differs significantly between ancestral back-
grounds, which corresponds to clinical differences in the dis-
ease between ancestral backgrounds. A Methods article by Feng
et al. examines public domain gene expression data to doc-
ument patterns of type I interferon-induced gene expression
and infer both positive and negative regulation by transcription
factors (9).
The Research Topic also features a number of Review Articles
focusing on various disease states. Liu et al. review murine mod-
els of systemic lupus erythematosus that are interferon-inducible,
providing model systems of autoimmunity related to type I inter-
feron (10). Wu et al. review the role of type I interferon in systemic
sclerosis, a distinct autoimmune disease characterized by thick-
ening and fibrosis of the skin, which shares a type I interferon
signature with other autoimmune conditions (11). Li et al. review
the evidence supporting a role for type I interferon in the patho-
genesis of Sjogren’s syndrome, spanning genetic associations, gene
expression studies, and clinical features of the disease (12). Reder
et al. review the contrasting role of type I interferon in multiple
sclerosis and systemic lupus erythematosus and other autoim-
mune conditions (13). In multiple sclerosis, type I interferon
levels are low (14), and administration of recombinant type I
interferon is an effective treatment. They review the evidence sup-
porting multiple sclerosis as a low interferon autoimmune disease,
and speculate on immunological features that might underlie this
striking difference. Shrivastav et al. review the role of nucleic acid
receptors in type I interferon generation in systemic lupus erythe-
matosus (15), a disease characterized by pathological activation
of the type I interferon pathway. These articles taken together
provide an overview of many of the ways type I interferons have
been implicated in human autoimmune disease, providing a fas-
cinating window into the biology of the human immune system
gone wrong.
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